Pressure BioSciences, Inc.
375 West Street
West Bridgewater
Massachusetts
02379-1040
United States
Tel: 508-580-1900
Fax: 508-580-1110
349 articles about Pressure BioSciences, Inc.
-
Uncle Bud’s to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness
2/5/2024
Pressure BioSciences, Inc. is hosting a teleconference today (Monday, February 5th, 4:30PM EST) to discuss the recent acquisition of natural health and wellness innovator Uncle Bud’s (“UB”), as well as other on-going opportunities.
-
Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction
1/22/2024
Pressure BioSciences, Inc. today announced the closing of its acquisition of natural health and wellness leader Uncle Bud’s (“UB”) in an all-stock transaction.
-
Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud’s, Forward Integrating PBIO’s UltraShear Platform into Multiple Markets
1/11/2024
Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud’s, Forward Integrating PBIO’s UltraShear Platform into Multiple Markets.
-
Pressure BioSciences’ BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies
1/4/2024
Pressure BioSciences, Inc. announced they are actively pursuing and evaluating multiple artificial intelligence and machine learning prospective partnerships.
-
Pressure BioSciences' Celebrates Second Groundbreaking Article Published This Month on its Transformative, Patented UltraShear Technology Processing Platform
12/21/2023
Pressure BioSciences, Inc. today announced the publication of a powerful visionary article in the respected industry trade magazine "Food Technology" published by the Institute of Food Technologists ("IFT").
-
Pressure BioSciences, Inc. Reports Q3 2023 Financial Results, Provides Business Update, and Offers Guidance for Remainder of 2023
11/21/2023
Pressure BioSciences, Inc. today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.
-
Pressure BioSciences' Patented BaroFold Technology Platform for High Efficiency Biopharmaceuticals Manufacturing Featured at International Bioprocess Conference by Leading Global Contract Biologics Manufacturer
11/2/2023
Pressure BioSciences, Inc. reported that Company scientists collaborating with scientists from Lonza Biologics presented convincing evidence that the Company's patented BaroFoldTM high-pressure protein disaggregation and refolding process provides significant advantages in cost, efficiency, and environmental impact remediation over current methods widely employed in biomanufacturing protein drugs, a market expected to reach $488 billion by 2030.
-
Pressure BioSciences Announces Exclusive Distribution Agreement with One of India’s Premier Distributors of Lab Automation, Instruments, and Consumables
10/18/2023
Pressure BioSciences, Inc. announced its partnership with Bioscreen Instruments PVT LTD, launching an exclusive instrument and consumables distribution agreement for India.
-
Pressure BioSciences Continues Expansion of IP Portfolio of Revolutionary UltraShear Technology with Award of First Canadian Patent
10/10/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced the award of the first Canadian patent for its revolutionary UltraShearTM Technology (UltraShearTM or USTTM) platform.
-
Pressure BioSciences’ Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately
9/22/2023
Pressure BioSciences, Inc. today announced that VST has increased its existing purchase order with PBIO by 10-fold (from 500 to 5,000 bottles), effective immediately.
-
Pressure BioSciences’ BaroFold Technology Achieves Pivotal Equipment Sale and Begins Scale-up in Service to Leading Global Contract Devt. & Mfg. Organization
9/8/2023
Pressure BioSciences, Inc. announced a key transition in its collaborations with multiple leaders and innovators in global biopharmaceutical development and commercialization, including preeminent Contract Development and Manufacturing Organizations.
-
Pressure BioSciences, Inc. Reports Q2 2023 Financial Results, Provides Business Update, and Offers Guidance for 2nd Half 2023
8/22/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today reported financial results for the second quarter ended June 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.
-
Third Round of Consumer Testing Strongly Validates Rapid Absorption and Effectiveness of Pressure BioSciences UltraShear Processed Nano-THC Oral Spray
6/27/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or "Company") today announced results from a third round of consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and under the tongue.
-
Pressure BioSciences, Inc. Q1 2023 Financial Results Achieve All-Time Quarterly Record
5/16/2023
Pressure BioSciences, Inc. reported that record quarterly financial results for any fiscal quarter was achieved in the first quarter ended March 31, 2023.
-
Extended Consumer Testing Strongly Validates Market Transforming Speed and Dosing Efficiency of Pressure BioSciences UltraShear Processed Nano-THC Oral Spray
5/9/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or "Company") today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks.
-
Pressure BioSciences Updates Rapid Progress on Limited Offering of Exclusive THC Licenses for Revolutionary UltraShear Nanoemulsion Processing Platform
4/26/2023
Pressure BioSciences, Inc. today provided a progress update on their exciting April 21, 2023, announcement.
-
Pressure BioSciences, Inc. Reports Q4 and FY 2022 Financial Results, Provides Business Update, and Offers Guidance for a Strong 2023
4/14/2023
Pressure BioSciences, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022, provided a business update, and offered guidance for a strong 2023, beginning with record revenue in the 2023 first quarter.
-
Pressure BioSciences, Inc. to Discuss Fiscal Year 2022 Financial Results and Provide 2023 Business Update and Guidance
4/13/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fiscal Year 2022 financial results and to provide a business update.
-
Pressure BioSciences and NutraLife Biosciences Renew Partnership for Development and Distribution of Next Generation Nutraceuticals
4/6/2023
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company") and NutraLife Biosciences (OTC Markets: NLBS) ("NLBS"), a highly-respected manufacturer and distributor of nutraceuticals primarily sold on a direct-to-consumer basis, today announced they have renewed collaborative efforts initiated four years ago.
-
Pressure BioSciences Reports Fresh Sales Momentum for PBI Agrochem
3/28/2023
Pressure BioSciences, Inc. and its wholly-owned subsidiary PBI Agrochem, Inc. announced it has shipped and billed an initial $130,000 order for its potent, environmentally-responsible nematode control product.